David obtained a bachelors degree in chemistry at M.I.T., followed by M.D. and Ph.D. degrees at Johns Hopkins. He was a medical resident at Brigham and Women’s Hospital and a medical oncology fellow at Dana-Farber/Harvard Cancer Center. During his post-doctoral years in Boston, David co-developed KIT inhibitors for gastrointestinal stromal tumors with Dr George Demetri. Simultaneously, he generated several widely-used mouse cancer models with Dr Tyler Jacks. As an independent investigator, David’s lab developed the first mouse models of ductal pancreatic cancer at the University of Pennsylvania. Subsequently, he was recruited to the University of Cambridge, UK, where his lab identified poor drug delivery as a barrier for therapeutic efficacy in pancreatic cancer. He was then recruited to Cold Spring Harbor Laboratory (CSHL) as the Deputy Director of the Cancer Center and to serve as Director of Research for the Lustgarten Foundation. At CSHL, his lab co-developed pancreatic organoid cancer models with Prof. Dr Hans Clevers, and made a series of observations regarding cancer fibroblasts, redox regulation, and pancreatitis. His awards include the Rita Allen Scholarship and the Jan Waldenström Award, and the Hamdan Award.